RESUMEN
Schistosomiasis remains a major global health problem. Despite large-scale schistosomiasis control efforts, clear limitations such as possible emergence of drug resistance and reinfection rates highlight the need for an effective schistosomiasis vaccine. Schistosoma mansoni large subunit of calpain (Sm-p80)-based vaccine formulations have shown remarkable efficacy in protecting against S. mansoni challenge infections in mice and baboons. In this study, we evaluated the cross-species protective efficacy of Sm-p80 vaccine against S. japonicum and S. haematobium challenge infections in rodent models. We also elucidated the expression of Sm-p80 and Sm-p80 ortholog proteins in different developmental stages of S. mansoni, S. haematobium, and S. japonicum. Immunization with Sm-p80 vaccine reduced worm burden by 46.75% against S. japonicum challenge infection in mice. DNA prime/protein boost (1 + 1 dose administered on a single day) resulted in 26.95% reduction in worm burden in S. haematobium-hamster infection/challenge model. A balanced Th1 (IFN-γ, TNF-α, IL-2, and IL-12) and Th2 (IL-4, IgG1) type of responses were observed following vaccination in both S. japonicum and S. haematobium challenge trials and these are associated with the prophylactic efficacy of Sm-p80 vaccine. Immunohistochemistry demonstrated that Sm-p80/Sm-p80 ortholog proteins are expressed in different life cycle stages of the three major human species of schistosomes studied. The data presented in this study reinforce the potential of Sm-p80-based vaccine for both hepatic/intestinal and urogenital schistosomiasis occurring in different geographical areas of the world. Differential expression of Sm-p80/Sm-p80 protein orthologs in different life cycle makes this vaccine potentially useful in targeting different levels of infection, disease, and transmission.
Asunto(s)
Antígenos Helmínticos/inmunología , Vacunas Antiprotozoos/inmunología , Schistosoma haematobium/inmunología , Schistosoma japonicum/inmunología , Schistosoma mansoni/inmunología , Esquistosomiasis Urinaria/prevención & control , Esquistosomiasis Japónica/prevención & control , Esquistosomiasis mansoni/prevención & control , Animales , Anticuerpos Antihelmínticos/inmunología , Calpaína/inmunología , Cricetinae , Modelos Animales de Enfermedad , Femenino , Humanos , Inmunoglobulina G/inmunología , Interleucina-12/biosíntesis , Interleucina-2/biosíntesis , Interleucina-4/biosíntesis , Masculino , Ratones , Ratones Endogámicos C57BL , Papio , Schistosoma haematobium/crecimiento & desarrollo , Schistosoma japonicum/crecimiento & desarrollo , Schistosoma mansoni/crecimiento & desarrollo , Esquistosomiasis Urinaria/inmunología , Esquistosomiasis Urinaria/parasitología , Esquistosomiasis Japónica/inmunología , Esquistosomiasis Japónica/parasitología , Esquistosomiasis mansoni/inmunología , Esquistosomiasis mansoni/parasitología , Factor de Necrosis Tumoral alfa/biosíntesis , Vacunación , Vacunas de ADN/inmunologíaRESUMEN
Based on data obtained using vaccine efficacy studies in mice, hamsters, and baboons, the credentials of Sm-p80 as a first tier vaccine candidate for schistosomiasis have been well established. Sm-p80-based vaccine formulation(s) have consistently exhibited potent prophylactic efficacy in reducing adult worm burden following cercarial challenge and induce killing of established adult worms in chronic infection. This vaccine is protective against both intestinal and urinary schistosomiasis. In this study, the longevity of Sm-p80-specific antibody responses was studied in mice and in baboons. Robust antibody titers were detected in mice for up to 60 weeks following vaccination with Sm-p80 recombinant vaccine (Sm-p80 + GLA-SE). In the follow-up experiments to our published studies, Sm-p80-specific IgG was also detected in baboons 5-8 years following the initial vaccination with an Sm-p80 DNA vaccine. In one baboon, transfer of Sm-p80-specific antibody was detected in umbilical cord blood and in the baby. These long-lasting humoral immune response data coupled with the vaccine efficacy data in rodents and nonhuman primates further strengthens the case for Sm-p80 to be moved forward through development leading to human clinical trials.
Asunto(s)
Anticuerpos Antihelmínticos/sangre , Schistosoma mansoni/inmunología , Esquistosomiasis mansoni/prevención & control , Vacunas/inmunología , Animales , Antígenos Helmínticos/inmunología , Biomphalaria/parasitología , Cricetinae , Femenino , Sangre Fetal/química , Sangre Fetal/inmunología , Inmunidad Materno-Adquirida , Inmunoglobulina G/sangre , Ratones , Papio , Embarazo , Schistosoma mansoni/genética , Vacunación , Vacunas de ADN/inmunologíaRESUMEN
Primary amebic meningoencephalitis (PAM) is a fulminant fatal human disease caused by the free-living amoeba Naegleria fowleri. Infection occurs after inhalation of water containing the amoeba, typically after swimming in bodies of warm freshwater. N. fowleri migrates to the brain where it incites meningoencephalitis and cerebral edema leading to death of the patient 7 to 10 days postinfection. Although the disease is rare, it is almost always fatal and believed to be underreported. The incidence of PAM in countries other than the United States is unclear and possibly on track to being an emerging disease. Poor prognosis is caused by rapid progression, suboptimal treatment, and underdiagnosis. As diagnosis is often performed postmortem and testing is only performed by a few laboratories, more accessible testing is necessary. This article reviews the current methods used in the screening and confirmation of PAM and makes recommendations for improved diagnostic practices and awareness.
Asunto(s)
Amebiasis , Infecciones Protozoarias del Sistema Nervioso Central , Meningoencefalitis , Naegleria fowleri , Humanos , Estados Unidos/epidemiología , Infecciones Protozoarias del Sistema Nervioso Central/diagnóstico , Encéfalo , Meningoencefalitis/diagnóstico , Técnicas de Laboratorio Clínico , Amebiasis/diagnósticoRESUMEN
BACKGROUND: Schistosomiasis continues to inflict significant morbidity and mortality in the tropical and subtropical regions of the world. The disease endemicity overlaps with the transmission of other parasitic diseases. Despite the ubiquity of polyparasitism in tropical regions, particularly in rural communities, little is known about the impact of multiple helminth infections on disease progression. In this pilot study, we describe the influence of chronic Trichuris trichiura infection on Schistosoma mansoni egg-induced hepatopathology in infected baboons. METHODS: Baboons with or without underlying whipworm infection were challenged with S. mansoni cercariae to establish schistosomiasis. Adult S. mansoni worms were recovered by perfusion and enumerated, hepatic granulomas were quantified via light microscopy, and transcriptional profiling of tissues were completed using RNA sequencing technologies. RESULTS: Co-infection with both S. mansoni and T. trichiura resulted in higher female schistosome worm burden and significantly larger liver granuloma sizes. Systems biology analyses of peripheral blood mononuclear cells (PBMC) revealed pathways associated with increased liver damage in co-infected baboons. CONCLUSIONS: Underlying chronic whipworm infection intensified schistosome egg-induced liver pathology in infected baboons. RNA-Seq analysis provided insight into pathways associated with increased liver damage, corroborating histological findings.
Asunto(s)
Coinfección/patología , Coinfección/veterinaria , Parasitosis Hepáticas/patología , Parasitosis Hepáticas/veterinaria , Esquistosomiasis/patología , Esquistosomiasis/veterinaria , Tricuriasis/patología , Tricuriasis/veterinaria , Enfermedades de los Animales/parasitología , Enfermedades de los Animales/patología , Animales , Enfermedad Crónica , Coinfección/parasitología , Femenino , Granuloma/patología , Humanos , Hígado/metabolismo , Hígado/parasitología , Hígado/patología , Parasitosis Hepáticas/parasitología , Masculino , Papio , Recuento de Huevos de Parásitos , Proyectos Piloto , Primates , Schistosoma mansoni , Esquistosomiasis/parasitología , Transcriptoma , Tricuriasis/parasitología , TrichurisRESUMEN
Recent advances in systems biology have shifted vaccine development from a largely trial-and-error approach to an approach that promote rational design through the search for immune signatures and predictive correlates of protection. These advances will doubtlessly accelerate the development of a vaccine for schistosomiasis, a neglected tropical disease that currently affects over 250 million people. For over 15 years and with contributions of over 120 people, we have endeavored to test and optimize Sm-p80-based vaccines in the non-human primate model of schistosomiasis. Using RNA-sequencing on eight different Sm-p80-based vaccine strategies, we sought to elucidate immune signatures correlated with experimental protective efficacy. Furthermore, we aimed to explore the role of antibodies through in vivo passive transfer of IgG obtained from immunized baboons and in vitro killing of schistosomula using Sm-p80-specific antibodies. We report that passive transfer of IgG from Sm-p80-immunized baboons led to significant worm burden reduction, egg reduction in liver, and reduced egg hatching percentages from tissues in mice compared to controls. In addition, we observed that sera from Sm-p80-immunized baboons were able to kill a significant percent of schistosomula and that this effect was complement-dependent. While we did not find a universal signature of immunity, the large datasets generated by this study will serve as a substantial resource for further efforts to develop vaccine or therapeutics for schistosomiasis.
Asunto(s)
Anticuerpos Antihelmínticos/farmacología , Antígenos Helmínticos/inmunología , Helmintiasis Animal/prevención & control , Inmunización Pasiva , Vacunas/inmunología , Animales , Anticuerpos Antihelmínticos/inmunología , Modelos Animales de Enfermedad , Helmintiasis Animal/inmunología , Ratones , Ratones Endogámicos C57BL , Papio , Schistosoma mansoni , Esquistosomiasis mansoniRESUMEN
Schistosomiasis is of public health importance to an estimated one billion people in 79 countries. A vaccine is urgently needed. Here, we report the results of four independent, double-blind studies of an Sm-p80-based vaccine in baboons. The vaccine exhibited potent prophylactic efficacy against transmission of Schistosoma mansoni infection and was associated with significantly less egg-induced pathology, compared with unvaccinated control animals. Specifically, the vaccine resulted in a 93.45% reduction of pathology-producing female worms and significantly resolved the major clinical manifestations of hepatic/intestinal schistosomiasis by reducing the tissue egg-load by 89.95%. A 35-fold decrease in fecal egg excretion in vaccinated animals, combined with an 81.51% reduction in hatching of eggs into the snail-infective stage (miracidia), demonstrates the parasite transmission-blocking potential of the vaccine. Substantially higher Sm-p80 expression in female worms and Sm-p80-specific antibodies in vaccinated baboons appear to play an important role in vaccine-mediated protection. Preliminary analyses of RNA sequencing revealed distinct molecular signatures of vaccine-induced effects in baboon immune effector cells. This study provides comprehensive evidence for the effectiveness of an Sm-p80-based vaccine for schistosomiasis.
Asunto(s)
Vacunas Antiprotozoos , Esquistosomiasis , Animales , Femenino , Masculino , Anticuerpos Antiprotozoarios/biosíntesis , Anticuerpos Antiprotozoarios/inmunología , Método Doble Ciego , Perfilación de la Expresión Génica , Papio , Recuento de Huevos de Parásitos , Proteínas Protozoarias/inmunología , Vacunas Antiprotozoos/administración & dosificación , Vacunas Antiprotozoos/genética , Vacunas Antiprotozoos/inmunología , Reacción en Cadena en Tiempo Real de la Polimerasa , Reproducibilidad de los Resultados , Schistosoma mansoni/inmunología , Esquistosomiasis/prevención & control , Esquistosomiasis/transmisión , Esquistosomiasis/veterinaria , Transcripción GenéticaRESUMEN
Sm-p80-based vaccine efficacy for Schistosoma mansoni was evaluated in a baboon model of infection and disease. The study was designed to replicate a human vaccine implementation scenario for endemic regions in which vaccine would be administered following drug treatment of infected individuals. In our study, the Sm-p80-based vaccine reduced principal pathology producing hepatic egg burdens by 38.0% and egg load in small and large intestines by 72.2% and 49.4%, respectively, in baboons. Notably, hatching rates of eggs recovered from liver and small and large intestine of vaccinated animals were significantly reduced, by 60.4%, 48.6%, and 82.3%, respectively. Observed reduction in egg maturation/hatching rates was supported by immunofluorescence and confocal microscopy showing unique differences in Sm-p80 expression in worms of both sexes and matured eggs. Vaccinated baboons had a 64.5% reduction in urine schistosome circulating anodic antigen, a parameter that reflects worm numbers/health status in infected hosts. Preliminary analyses of RNA sequencing revealed unique genes and canonical pathways associated with establishment of chronic disease, praziquantel-mediated parasite killing, and Sm-p80-mediated protection in vaccinated baboons. Overall, our study demonstrated efficacy of the Sm-p80 vaccine and provides insight into some of the epistatic interactions associated with protection.
Asunto(s)
Praziquantel/uso terapéutico , Schistosoma mansoni/inmunología , Esquistosomiasis mansoni/inmunología , Vacunación/métodos , Vacunas/inmunología , Animales , Antihelmínticos/uso terapéutico , Anticuerpos Antihelmínticos/inmunología , Antígenos Helmínticos/inmunología , Enfermedad Crónica , Femenino , Humanos , Masculino , Recuento de Huevos de Parásitos , Schistosoma mansoni/efectos de los fármacos , Schistosoma mansoni/fisiología , Esquistosomiasis mansoni/parasitología , Esquistosomiasis mansoni/terapia , Resultado del Tratamiento , Vacunas/administración & dosificaciónRESUMEN
Schistosomiasis is a neglected parasitic disease of major public health concern as it affects over 250 million people in developing countries. Currently there is no licensed vaccine available against schistosomiasis. The Schistosoma mansoni calpain protein, Sm-p80, is a leading vaccine candidate now ready to move to clinical trials. In order to better assess Sm-p80 vaccine immunogenicity; here we used a systems biology approach employing RNA-sequencing to identify gene signatures and epistatic interactions following Sm-p80 vaccination in mouse and baboon models that may predict vaccine efficacy. Recombinant Sm-p80 + CpG-oligodeoxynucleotide (ODN) vaccine formulation induced both cellular and humoral immunity genes with a predominant TH1 response as well as TH2 and TH17 gene signatures. Early gene responses and gene-network interactions in mice immunized with rSm-p80 + ODN appear to be initiated through TLR4 signaling. CSF genes, S100A alarmin genes and TNFRSF genes appear to be a signature of vaccine immunogenicity/efficacy as identified by their participation in gene network interactions in both mice and baboons. These gene families may provide a basis for predicting desirable outcomes for vaccines against schistosomiasis leading to a better understanding of the immune system response to vaccination.
Asunto(s)
Antígenos Helmínticos/inmunología , Schistosoma mansoni/inmunología , Esquistosomiasis mansoni/inmunología , Vacunas/inmunología , Animales , Anticuerpos Antihelmínticos/inmunología , Epistasis Genética/genética , Epistasis Genética/inmunología , Femenino , Redes Reguladoras de Genes/genética , Redes Reguladoras de Genes/inmunología , Inmunidad Celular/genética , Inmunidad Celular/inmunología , Inmunidad Humoral/genética , Inmunidad Humoral/inmunología , Masculino , Ratones Endogámicos C57BL , Oligodesoxirribonucleótidos/administración & dosificación , Oligodesoxirribonucleótidos/inmunología , Papio , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Schistosoma mansoni/metabolismo , Schistosoma mansoni/fisiología , Esquistosomiasis mansoni/parasitología , Esquistosomiasis mansoni/prevención & control , Transducción de Señal/genética , Transducción de Señal/inmunología , Transcriptoma/genética , Transcriptoma/inmunología , Vacunación/métodos , Vacunas/administración & dosificaciónRESUMEN
Schistosomiasis is a neglected tropical disease (NTD) of public health importance. Despite decades of implementation of mass praziquantel therapy programs and other control measures, schistosomiasis has not been contained and continues to spread to new geographic areas. A schistosomiasis vaccine could play an important role as part of a multifaceted control approach. With regards to vaccine development, many biological bottlenecks still exist: the lack of reliable surrogates of protection in humans; immune interactions in co-infections with other diseases in endemic areas; the potential risk of IgE responses to antigens in endemic populations; and paucity of appropriate vaccine efficacy studies in nonhuman primate models. Research is also needed on the role of modern adjuvants targeting specific parts of the innate immune system to tailor a potent and protective immune response for lead schistosome vaccine candidates with the long-term aim to achieve curative worm reduction. This review summarizes the current status of schistosomiasis vaccine development.